Compare RYAN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYAN | TVTX |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.1B |
| IPO Year | 2021 | 2013 |
| Metric | RYAN | TVTX |
|---|---|---|
| Price | $32.56 | $45.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $50.88 | $40.62 |
| AVG Volume (30 Days) | ★ 2.2M | 2.0M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,051,126,000.00 | N/A |
| Revenue This Year | $15.78 | $44.76 |
| Revenue Next Year | $12.49 | $35.51 |
| P/E Ratio | $86.72 | ★ N/A |
| Revenue Growth | ★ 21.28 | N/A |
| 52 Week Low | $29.28 | $13.88 |
| 52 Week High | $68.70 | $48.61 |
| Indicator | RYAN | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 58.73 |
| Support Level | $31.50 | $41.43 |
| Resistance Level | $34.41 | $48.60 |
| Average True Range (ATR) | 1.50 | 2.02 |
| MACD | 0.08 | -0.24 |
| Stochastic Oscillator | 49.26 | 65.70 |
Ryan Specialty Holdings Inc is an international specialty insurance intermediary providing specialty products, solutions, and services for insurance brokers, agents, and carriers. The company offers wholesale insurance brokerage and delegated underwriting authority products and services, including distribution, underwriting, product development, administration, and risk management. Its expertise spans property, casualty, professional lines, transportation, personal lines, workers compensation, and employee benefits insurance, across traditional insurance and alternative risk solutions. The company operates in the United States and foreign markets, with the majority of revenue generated from the United States.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.